These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18329876)

  • 21. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.
    Choi-Sledeski YM; Kearney R; Poli G; Pauls H; Gardner C; Gong Y; Becker M; Davis R; Spada A; Liang G; Chu V; Brown K; Collussi D; Leadley R; Rebello S; Moxey P; Morgan S; Bentley R; Kasiewski C; Maignan S; Guilloteau JP; Mikol V
    J Med Chem; 2003 Feb; 46(5):681-4. PubMed ID: 12593648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Koch S; Rossi KA; Alexander RS; Smallwood A; Wong PC; Rendina AR; Luettgen JM; Knabb RM; He K; Xin B; Wexler RR; Lam PY
    J Med Chem; 2007 Nov; 50(22):5339-56. PubMed ID: 17914785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
    Smallheer JM; Alexander RS; Wang J; Wang S; Nakajima S; Rossi KA; Smallwood A; Barbera F; Burdick D; Luettgen JM; Knabb RM; Wexler RR; Jadhav PK
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5263-7. PubMed ID: 15454208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.
    Qiao JX; Cheney DL; Alexander RS; Smallwood AM; King SR; He K; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4118-23. PubMed ID: 18550370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.
    Klein SI; Czekaj M; Gardner CJ; Guertin KR; Cheney DL; Spada AP; Bolton SA; Brown K; Colussi D; Heran CL; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
    J Med Chem; 1998 Feb; 41(4):437-50. PubMed ID: 9484495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues.
    Qiao JX; Cheng X; Smallheer JM; Galemmo RA; Drummond S; Pinto DJ; Cheney DL; He K; Wong PC; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1432-7. PubMed ID: 17174550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification.
    Komoriya S; Kobayashi S; Osanai K; Yoshino T; Nagata T; Haginoya N; Nakamoto Y; Mochizuki A; Nagahara T; Suzuki M; Shimada T; Watanabe K; Isobe Y; Furugoori T
    Bioorg Med Chem; 2006 Mar; 14(5):1309-30. PubMed ID: 16263291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.
    Meneyrol J; Follmann M; Lassalle G; Wehner V; Barre G; Rousseaux T; Altenburger JM; Petit F; Bocskei Z; Schreuder H; Alet N; Herault JP; Millet L; Dol F; Florian P; Schaeffer P; Sadoun F; Klieber S; Briot C; Bono F; Herbert JM
    J Med Chem; 2013 Dec; 56(23):9441-56. PubMed ID: 24175584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
    Roehrig S; Straub A; Pohlmann J; Lampe T; Pernerstorfer J; Schlemmer KH; Reinemer P; Perzborn E
    J Med Chem; 2005 Sep; 48(19):5900-8. PubMed ID: 16161994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
    Quan ML; Han Q; Fevig JM; Lam PY; Bai S; Knabb RM; Luettgen JM; Wong PC; Wexler RR
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1795-8. PubMed ID: 16434195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
    Shi Y; Sitkoff D; Zhang J; Han W; Hu Z; Stein PD; Wang Y; Kennedy LJ; O'Connor SP; Ahmad S; Liu EC; Seiler SM; Lam PY; Robl JA; Macor JE; Atwal KS; Zahler R
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5952-8. PubMed ID: 17855089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure- and property-based design of factor Xa inhibitors: pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs.
    Young RJ; Campbell M; Borthwick AD; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Crowe MC; Dayal S; Diallo H; Kelly HA; King NP; Kleanthous S; Mason AM; Mordaunt JE; Patel C; Pateman AJ; Senger S; Shah GP; Smith PW; Watson NS; Weston HE; Zhou P
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5953-7. PubMed ID: 16982190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
    Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
    J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of imidazo[1,5-c]imidazol-3-ones: weakly basic, orally active factor Xa inhibitors.
    Imaeda Y; Kuroita T; Sakamoto H; Kawamoto T; Tobisu M; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
    J Med Chem; 2008 Jun; 51(12):3422-36. PubMed ID: 18507371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.
    Kleanthous S; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chan C; Clarte MO; Convery MA; Harling JD; Hortense E; Irving WR; Irvine S; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Roethka TJ; Senger S; Shah GP; Stelman GJ; Toomey JR; Watson NS; West RI; Whittaker C; Zhou P; Young RJ
    Bioorg Med Chem Lett; 2010 Jan; 20(2):618-22. PubMed ID: 20006499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR.
    Zhang P; Bao L; Fan J; Jia ZJ; Sinha U; Wong PW; Park G; Hutchaleelaha A; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2186-9. PubMed ID: 19297158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.
    Shi Y; Sitkoff D; Zhang J; Klei HE; Kish K; Liu EC; Hartl KS; Seiler SM; Chang M; Huang C; Youssef S; Steinbacher TE; Schumacher WA; Grazier N; Pudzianowski A; Apedo A; Discenza L; Yanchunas J; Stein PD; Atwal KS
    J Med Chem; 2008 Dec; 51(23):7541-51. PubMed ID: 18998662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.
    Ye B; Arnaiz DO; Chou YL; Griedel BD; Karanjawala R; Lee W; Morrissey MM; Sacchi KL; Sakata ST; Shaw KJ; Wu SC; Zhao Z; Adler M; Cheeseman S; Dole WP; Ewing J; Fitch R; Lentz D; Liang A; Light D; Morser J; Post J; Rumennik G; Subramanyam B; Sullivan ME; Vergona R; Walters J; Wang YX; White KA; Whitlow M; Kochanny MJ
    J Med Chem; 2007 Jun; 50(13):2967-80. PubMed ID: 17536795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of transition state factor Xa inhibitors as potential anticoagulant agents.
    Zhu BY; Huang W; Su T; Marlowe C; Sinha U; Hollenbach S; Scarborough RM
    Curr Top Med Chem; 2001 Jun; 1(2):101-19. PubMed ID: 11899247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.